EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mucins as anti-cancer targets: perspectives of the glycobiologist

Inka Brockhausen iD, Jacob Melamed

Glycoconjugate Journal · 2021-08 · 38 (4) · 459-474

DOI: 10.1007/s10719-021-09986-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Glycoconjugate Journal, online erschienen am 11.03.2021. Verfasst von Inka Brockhausen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical and Molecular Sciences, Queen's University, 18 Stuart St, Kingston, ON, K7L 3N6, Canada. brockhau@queensu.ca. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 132 Literaturangaben. Gefördert von: Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucins are highly O-glycosylated glycoproteins that carry a heterogenous variety of O-glycan structures. Tumor cells tend to overexpress specific mucins, such as the cell surface mucins MUC1 and MUC4 that are engaged in signaling and cell growth, and exhibit abnormal glycosylation. In particular, the Tn and T antigens and their sialylated forms are common in cancer mucins. We review herein methods chosen to use cancer-associated glycans and mucins as targets for the design of anti-cancer immunotherapies. Mucin peptides from the glycosylated and transmembrane domains have been combined with immune-stimulating adjuvants in a wide variety of approaches to produce anti-tumor antibodies and vaccines. These mucin conjugates have been tested on cancer cells in vitro and in mice with significant successes in stimulating anti-tumor responses. The clinical trials in humans, however, have shown limited success in extending survival. It seems critical that the individual-specific epitope expression of cancer mucins is considered in future therapies to result in lasting anti-tumor responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesHumansMembrane GlycoproteinsMucinsNeoplasms

Stichwörter der Autor:innen

Anti-mucin antibodiesCancerEpitopesGlycopeptidesImmunotherapyMUC1MUC4MucinO-glycansVaccine

Substanzen

Cancer VaccinesMembrane GlycoproteinsMucins

Autor:innen und Institutionen

  • Biomedical and Molecular Sciences, Queen's University, 18 Stuart St, Kingston, ON, K7L 3N6, Canada. brockhau@queensu.ca.
  • Biomedical and Molecular Sciences, Queen's University, 18 Stuart St, Kingston, ON, K7L 3N6, Canada.

ORCID-Profile: Inka Brockhausen

Förderung

  • Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Brockhausen, I., & Melamed, J. (2021). Mucins as anti-cancer targets: perspectives of the glycobiologist. Glycoconjugate Journal, 38(4), 459-474. https://doi.org/10.1007/s10719-021-09986-8

Vancouver

Brockhausen I, Melamed J. Mucins as anti-cancer targets: perspectives of the glycobiologist. Glycoconjugate Journal. 2021;38(4):459-474. doi:10.1007/s10719-021-09986-8

BibTeX
@article{Brockhausen2021,
  author = {Brockhausen, Inka and Melamed, Jacob},
  title = {Mucins as anti-cancer targets: perspectives of the glycobiologist},
  journal = {Glycoconjugate Journal},
  year = {2021},
  volume = {38},
  number = {4},
  pages = {459--474},
  doi = {10.1007/s10719-021-09986-8}
}
Kostenlos starten →